We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

By LabMedica International staff writers
Posted on 01 May 2024

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. More...

Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead to blood cancers. Interestingly, it is also present in individuals with normal blood counts, where it is linked with a heightened risk of severe atherosclerotic cardiovascular disease. Studies have shown that clonal hematopoiesis becomes more common with age, being detectable in up to 15% of individuals over 70. While it can progress to malignant blood diseases, its significant impact is the reduction in life expectancy due to an increased risk of atherosclerotic cardiovascular disease, which at its advanced stage, can cause heart attacks and strokes due to arterial blockages.

Now, a research team at the Medical University of Vienna (Vienna, Austria) has designed a genetic testing method for detecting clonal hematopoiesis. Combined with an ultrasound examination of the carotid artery, this testing approach can identify individuals at high risk for cardiovascular disease. For their research, the team focused on the impact of clonal hematopoiesis on patients with asymptomatic, verified carotid stenosis—a narrowing of the carotid artery due to atherosclerosis. They developed a novel assay employing high-throughput DNA sequencing for targeted genetic testing to detect mutations that cause clonal hematopoiesis. This testing method was applied to around 1,000 blood samples from the ICARAS study (Inflammation and Carotid Artery-Risk for Atherosclerosis Study).

The study revealed a significant increase in mortality among patients who have both carotid stenosis and clonal hematopoiesis. The joint detection of clonal hematopoiesis and carotid atherosclerosis led to the identification of a new combined biomarker that enhances the personalization of cardiovascular risk profiles. This allows for the early identification of high-risk patients, which in turn facilitates the timely adjustment of treatment plans and the prevention of the progression of atherosclerotic diseases, thereby reducing the incidence of strokes and heart attacks.

By utilizing ultrasound-based duplex sonography along with this innovative genetic testing, elevated cardiovascular risk can now be detected well before any symptoms of the disease appear. According to the researchers, “the results of this study provide the basis for future studies to investigate the role of clonal haematopoiesis in cardiovascular diseases", with the goal of implementing such genetic diagnostics in laboratory medicine.

Related Links:
Medical University of Vienna


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.